<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000455153"><TermName>vorinostat</TermName><TermPronunciation>(vor-IN-oh-stat)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Vorinostat is a type of histone deacetylase inhibitor. Also called SAHA, suberoylanilide hydroxamic acid,  and Zolinza.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000703924" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vorinostat&quot;" language="en" id="_3"/><MediaLink ref="CDR0000703923" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vorinostat&quot;" language="es" id="_4"/><SpanishTermName>vorinostat</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el linfoma cutáneo de células T que no mejora, empeora o vuelve durante el tratamiento con otros medicamentos o después de este. También está en estudio para el tratamiento de otros tipos de cáncer. El vorinostat es un tipo de inhibidor de la histona desacetilasa. También se llama ácido hidroxámico suberoilanilida, AHSA,  y Zolinza.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-08-24</DateFirstPublished><DateLastModified>2008-11-14</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000513752">Vorinostat</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
